Sunday - June 2, 2024

Levosimendan for Treating Pulmonary Hypertension With Heart Failure With Preserved Ejection Fraction (PH-HFpEF)

2024-04-30

ALEXANDRIA, Virginia, April 30 -- TENAX THERAPEUTICS, INC., Chapel Hill, North Carolina has been assigned a patent (No. US 11969424 B2, initially filed Dec. 15, 2020) developed by three inventors Stuart Rich, Skokie, Illinois; Douglas Randall, Wake Forest, North Carolina; and Douglas Hay, Ottsville, Pennsylvania, for "Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)." . . .

Information Request Form

Name:
Category that best fits the type of business or agency you are affiliated with:	Government Newspaper / Media Business Public Policy Individual / Student Educators
Company Name:
Email:
Phone:
State:

I'd like to have a copy of this article mailed to me.

To also receive a free sample of other Targeted News products check the appropriate boxes below.
Golf Handicap site (FairwayFiles.com)
Products marked with ** can be customized by keywords or areas of interest. If you select them please specify your keywords in the box below:

If we need to contact you please specify your preferred contact method. Have a representative contact me by phone
Have a representative contact me via email

Additonal questions or comments:

Click here for more information or a free trial

Existing Customer Login

Levosimendan for Treating Pulmonary Hypertension With Heart Failure With Preserved Ejection Fraction (PH-HFpEF)

Information Request Form

Copyright Targeted News Service 2024